Fluosol-DA

Known as: FSOL 
A perfluorocarbon blood substitute in trials for the treatment of severe anemia
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1990
Highly Cited
1990
In order to investigate the effect of environmentally determined conditions on the cytotoxicity of anticancer treatments, Hoechst… (More)
  • table 1
  • table 2
Is this relevant?
1988
1988
The administration of a perfluorochemical emulsion and carbogen (95% O2, 5% CO2) breathing before photodynamic therapy (PDT) was… (More)
  • figure 1
  • figure 3
  • figure 2
  • table 1
  • figure 4
Is this relevant?
1987
1987
Fluosol-DA with carbogen (95% oxygen and 5% carbon dioxide) breathing can increase the efficacy of melphalan. Addition of Fluosol… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
1987
1987
The cytotoxicity of melphalan toward exponentially growing FSaIIC fibrosarcoma cells under hypoxia, normal aeration… (More)
Is this relevant?
1986
1986
We assessed the safety and efficacy of Fluosol-DA as a red-cell substitute in acute anemia. Twenty-three surgical patients with… (More)
Is this relevant?
1986
1986
The potential usefulness of i.v. injection of perfluorochemicals and breathing carbogen (95% O2 and 5% CO2) to improve the… (More)
Is this relevant?
1984
1984
Hemodynamic changes of 2 patients to a 0.5-ml test-dose infusion of Fluosol-DA 20% are presented. The first patient had the… (More)
Is this relevant?
1984
1984
To study the effect of a perfluorocarbon oxygen transport emulsion (Fluosol-DA) on reticuloendothelial system (RES) function, we… (More)
Is this relevant?
1982
1982
After the experimental and phase one studies of our so-called "artificial blood," Fluosol-DA (20%), an emulsified mixture of… (More)
Is this relevant?
1981
1981
Fluosol-DA (Perfluorochemical Blood Substitutes) are small particle fluorocarbons suspended in an emulsion and have a high… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?